Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Improved Overall Survival as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at Final Analysis of Pivotal Phase 3 KEYNOTE-048 Trial
Survival Benefit Now Observed with KEYTRUDA in Combination with Chemotherapy in All Patient Populations (Regardless of PD-L1 Expression) and with KEYTRUDA Monotherapy in Patients Whose Tumors Expressed PD-L1 at CPS ≥1
Data Presented Today at 2019 ASCO Annual Meeting
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the presentation of the final analysis of the pivotal
Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck’s anti-PD-1
therapy, as monotherapy and in combination with chemotherapy, for the
first-line treatment of patients with recurrent or metastatic head and
neck squamous cell carcinoma (HNSCC) at the 2019 American Society of
Clinical Oncology (ASCO) Annual Meeting (Abstract #6000).
Media:
Pamela Eisele
(267) 305-3558
or
Ayn Wisler
(908) 740-5590
Investors:
Teri Loxam
(908) 740-1986
or
Peter Dannenbaum
(908) 740-1037
